

NEW PROCESS FOR THE SYNTHESIS OF
SUBSTITUTED ALPHA-AMINOINDAN DERIVATIVES.


This invention relates to a new process to
5 prepare optically active substituted alpha-amino-indan
derivatives useful as synthetic intermediates for the
preparation of active pharmaceuticals.

According to the prior art document
WO98/27055, optically active substituted alpha-amino-
10 indan derivatives are prepared from an optically active
non-substituted alpha-amino-indane with a four steps
process in order to obtain optically active alpha-
amino-indan substituted compounds. This process
involves a Friedel & Craft reaction and a Bayer-
15 Villiger reaction. However, these two reactions show
some limitations such as low yields and safety issues.

According to this document optically active
substituted alpha-amino-indan derivatives are also
prepared from a racemic substituted alpha-amino-indan
20 compounds with an optical resolution process. The
limitations of this process are the low yields.

This invention describes a new process for
yielding to optically active substituted alpha-amino-
25 indane compounds of general formula (I) hereunder:

(I)



wherein :

m is an integer equal to 0, 1, 2 or 3,

preferably m is 0,


R₁ is a hydrogen atom, an alkyl group having
5 from 1 to 20 carbon atoms, an aryl group having from 6 to 20 carbon atoms, an alkylaryl group having from 6 to 20 carbon atoms, an alkaloyl group, an aryloyl group, preferably R₁ is an alkyl group having from 1 to 20 carbon atoms, and more preferably R₁ is an alkyl group
10 having from 1 to 4 carbon atoms, especially a methyl group,

which comprise :

- an asymmetric hydrogenation reaction of an en-amide derivative of formula (III)

15


(III)



wherein m and R₁ are as defined above,

R₂ is a hydrogen atom, an alkyl group having
20 from 1 to 20 carbon atoms, an aryl group having from 6 to 20 carbon atoms, an alkylaryl group having from 6 to 20 carbon atoms, preferably R₂ is an alkyl group having from 1 to 20 carbon atoms, and more preferably an alkyl group having from 1 to 4 carbon atoms, especially a
25 methyl in presence of hydrogen and an optically active catalyst, preferably an optically active asymmetric hydrogenation catalyst,

in order to obtain an amide derivative of formula (II) :



5

- a hydrolysis reaction of the amide derivative of formula (II) obtained in the previous step,

10 in order to obtain optically active substituted alpha-indanyl amide derivatives of formula (I).

15 The derivatives of formula (I) can be in a (R) configuration or in a (S) configuration. In the same way, the derivatives of formula (II) can be in a (R) configuration or in a (S) configuration.

20 In the present application the term alkyl means a straight or branched alkyl group having from 1 to 20 carbon atoms (such as but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, tert-butyl), optionally substituted with a lower alkyl group or a functional group.

25 The term aryl means an aryl group having from 6 to 20 carbon atoms (such as but not limited to phenyl, tolyl, xylyl, cumenyl, naphthyl), optionally

substituted with a lower alkyl group or a functional group, or a fused aryl or a heteroaryl group having from 6 to 20 carbon atoms (such as but not limited to furyl, thienyl, pyrrolyl, imidazolyl, pyridyl, pyrazyl, 5 pyrimidinyl, indolyl, carbazolyl, isoxazolyl, isothiazolyl).

The term alkylaryl means an alkylaryl group having from 6 to 20 carbon atoms (such as but not limited to benzyl, phenethyl, naphthylmethyl) 10 optionally substituted with a lower alkyl group or a functional group.

The term alkaloyl means preferably -COR1 wherein R1 is an alkyl group as defined above (such as but not limited to acetyl, propionyl or pivaloyl).


15 The term aryloyl means preferably -COR1 wherein R1 is an aryl group as defined above (such as but not limited to benzoyl or phenylacetyl).

The term lower alkyl means a straight or branched alkyl group having from 1 to 8 carbons atoms 20 (such as but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl or tert-butyl).


The term functional group means an halogen, -OH, -OR3, -CN, -COOR3, -COR3, -CONR3R4, -OCOR3, -NH2, 25 -NHR3, -NR3R4, -NHCOR3 and -N(COR3)2, -NO2, -SH, -SR3, wherein R3 and R4 are independently a lower alkyl, an alkylaryl or an aryl group as defined previously. The term halogen means an atom like chlore, brome, fluor or iodine.

30 The optically active catalyst used in the asymmetric hydrogenation of the en-amide derivative of formula (III) is represented by a chiral phosphine

transition metal complexe of formula (VIIA) or formula (VIIB):



5 or



wherein

10 M is a transition metal selected in the group comprising ruthenium (Ru), rhodium (Rh) and iridium (Ir) preferably M is ruthenium or rhodium.

15 X is a halogen atom selected in the group comprising chlorine (Cl), bromine (Br), fluorine (F) and iodine (I), preferably X is chlorine or bromine.

20 Z is an aryl group having from 6 to 20 carbon atoms or an unsaturated organic group, cyclic or not, selected in the group comprising olefine, diene and cyano, preferably diene and most preferably cyclooctadiene (COD).

25 L* is a chiral ligand selected in the group comprising the chiral diphosphine derivatives, the chiral atropoisomeric diphosphine derivatives, the chiral monodentate phosphoramide derivatives, the chiral biphospholane derivatives, the chiral ferrotane derivatives and the chiral ferrocenyl phosphine derivatives,

30 Y is an anion such as ClO_4^- , BF_4^- , PF_6^- , SbF_6^- , preferably BF_4^- .

35 S is a dialkyl ammonium, preferably a dimethyl ammonium.

j is an integer equal to 0 or 1.

i is an integer equal to 0, 1, 2 or 4.

n is an integer equal to 1 or 2.

The transition metal preferably means ruthenium or rhodium.

5 The aryl group is a benzene optionally substituted with an alkyl.

10 The olefin is selected in the group comprising pi-allyl and 1,3,5,7-cyclooctatetraene and the diene is selected in the group comprising 1,3-butadiene, 2,5-norbornadiene, 1,5-cyclooctadiene (COD) and cyclopentadiene.

The chiral diphosphine is selected in the group comprising BICP, DuPHOS, MiniPHOS, BDPMI, TangPHOS, P-PHOS, Tol-P-PHOS, Xyl-P-PHOS and BPE.

15 The chiral atropoisomeric diphosphine is selected in the group comprising BINAP, TolBINAP, MeOBIPHEP, BINAPO, SYNPHOS and BINAPO optionally ortho-substituted with an alkyl or an aryl.

20 The chiral monodentate phosphoramidine is selected in the group comprising Monophos and Ethylmonophos.

The chiral bisphospholane is selected in the group comprising Tangphos, Duphos, Me-Duphos, Me-BPE, Et-BPE, Binaphane and Malphos.

25 The chiral ferrocenyl phosphine is JOSIPHOS.

The chiral ligand is preferably a chiral atropoisomeric diphosphine or a chiral bisphospholane, most preferably BINAP, MeOBIPHEP, Tangphos, Me-BPE, Et-BPE or Binaphane.

30 The wellknown abbreviations listed above have the following meaning :

Concerning the chiral diphosphine derivatives :

BICP : (R,R)-2,2'-bis-diphenylphosphanyl-bicyclopentyl and other isomers.

5 MiniPHOS : 1,3-diphenyl-[1,3]diphospholane and other isomers.

BDPMI: 2-Imidazolidinone, 4,5-bis[(diphenylphosphino)methyl]-1,3-dimethyl-, (4S,5S)-and other isomers.

10 TangPHOS : 2,2'-Biphospholane, 1,1'-bis(1,1-dimethylethyl)-, (1S,1'S,2R,2'R) and other isomers.

P-PHOS : 3,3'-Bipyridine, 4,4'-bis(diphenylphosphino)-2,2',6,6'-tetramethoxy-, (3S) ;
15 or 3,3'-Bipyridine, 4,4'-bis(diphenylphosphino)-2,2',6,6'-tetramethoxy-, (3R) ;

Tol-P-PHOS : 3,3'-Bipyridine, 4,4'-bis(di-(4-methylphenyl)-phosphino)-2,2',6,6'-tetramethoxy-, (3S) ; or 3,3'-Bipyridine, 4,4'-bis(di-(4-methylphenyl)-phosphino)-2,2',6,6'-tetramethoxy-, (3R) ;

Xyl-P-Phos : 3,3'-Bipyridine, 4,4'-bis(di-(3,5-dimethylphenyl)-phosphino)-2,2',6,6'-tetramethoxy-, (3S) ; or 3,3'-Bipyridine, 4,4'-bis(di-(3,5-dimethylphenyl)-phosphino)-2,2',6,6'-tetramethoxy-, (3R) .

BPE : 1,2-bis(substituted-phospholano)ethane and other isomers.

Me-BPE : 1,2-(2,5-dimethylphospholano)ethane and other isomers

Concerning the atropoisomeric chiral diphosphines derivative :

BINAP : (R)-2,2'-Bis(diphenylphosphino)-
1,1'-binaphthyl or (S)-2,2'-Bis(diphenylphosphino)-
1,1'-binaphthyl ;

5 TolBINAP: (R)-2,2'-Bis(di-p-tolylphosphino)-1,1'-binaphthyl or (S)-2,2'-Bis(di-p-tolylphosphino)-1,1'-binaphthyl ;

MeOBIPHEP: (R)-2,2'-bis-diphenylphosphanyl-6,6'-dimethoxy-biphenyl or (S)-2,2'-bis-diphenylphosphanyl-6,6'-dimethoxy-biphenyl ;

10 BINAPO : (R)-[1,1'-Binaphthalene]-2,2'-diyl bis(diphenylphosphinite) or (S)-[1,1'-Binaphthalene]-2,2'-diyl bis(diphenylphosphinite) ;

SYNPHOS : -(R)-[2,3,2',3'-tetrahydro-5,5'-bi(1,4-benzodioxin)-6,6'-diyl]bis(diphenylphosphane) or
15 -(S)-[2,3,2',3'-tetrahydro-5,5'-bi(1,4-benzodioxin)-6,6'-diyl]bis(diphenylphosphane)

Concerning the chiral monodentate phosphoramidine derivative:

20 Monophos : Dinaphtho [2,1-d :1',2'-f] [1,3,2]dioxaphosphepin-4-amine, N,N-dimethyl-, (2aR) ; or
Dinaphtho [2,1-d :1',2'-f] [1,3,2]dioxaphosphepin-4-amine, N,N-dimethyl-, (11bS) ;

25 Concerning the chiral bisphospholane derivative:

Me-Duphos : 1,2-bis-((2R,5R)-2,5-dimethylphospholano)benzene or 1,2-bis-((2S,5S)-2,5-dimethylphospholano)benzene ;

30 DupHOS: bis(substituted-phospholano)benzene;

Concerning the chiral ferrocenyl phosphine derivative:

JOSIPHOS : (R)-1-[(S)-2-diphenylphosphino)-5-ferrocenyl]ethylidicyclohexylphosphine or (S)-1-[(R)-2-diphenylphosphino)-15-ferrocenyl]ethylidicyclohexylphosphine.

According to a preferred embodiment of the invention, the optically active catalyst of formula (VII) is Ru(COD)(MeOBIPHEP)BF₄⁻, Ru(COD)(BINAP)BF₄⁻ or Rh(COD)(Me-BPE)BF₄⁻. The catalyst can be *in situ* prepared or can a preformed complex.

The solvant used during the assymetric hydrogenation is selected in the group comprising ether such as tetrahydrofuran (THF), tetrahydropyran and diethyl ether, aromatic hydrocarbon such as benzene and toluene, halogenated hydrocarbon such as dichloromethane, alcohol such as methanol, ethanol or isopropanol. According to a preferred embodiment of the invention the solvant used is an alcohol, more preferably methanol.

The molar ratio of the en-amide derivative of formula (III) to the optically active catalyst (VII) used during the asymmetric hydrogenation is from 100/1 to 10000/1, preferably from 100/1 to 1000/1, more preferably from 200/1 to 1000/1, especially from 500/1 to 1000/1.

The hydrogen pressure used during the asymmetric hydrogenation is from 0,5 to 20 bar,

preferably from 0,5 to 10 bar, more preferably 1 to 8 bar, especially from 4 to 8 bar.

The temperature range used during the asymmetric hydrogenation is from - 20 to 100 °C,
5 preferably from 20 to 100°C, more preferably from 20°C to 60°C and especially from 40°C to 60°C, for a period of time in the range of 10 min to three days, preferably of one hour to three days, more preferably 1 hours to 1 day and especially 4 hours to 1 day.

10


The step of the hydrolysis reaction of the amide derivative of formula (II) obtained at the end of the assymetric hydrogenation is performed in presence of an organic acid or a mineral acid such as
15 hydrochloric acid, sulfuric acid or hydrobromic acid, preferably suilfuric acid, according to methods described in the literature to obtain alpha-aminoindan derivatives of formula (I) in an appropriate solvent, preferably an alcohol and more preferably methanol.

20

According to a preferred embodiment of the invention, the en-amide derivative of formula (III) is prepared by the two following step :

- an acylation reaction of an alpha-hydroxyimino-indane derivative of formula (V):
25

(V)



wherein R₁ and m are as defined above
in presence of an organic anhydride of
formula (VI) :


5



wherein R₂ and R'₂ identical or different
are a hydrogen atom, an alkyl group having from 1 to 20
carbon atoms, an aryl group having from 6 to 20 carbon
atoms, an alkylaryl group having from 6 to 20 carbon
atoms, preferably R₂ and R'₂ are an alkyl group having
from 1 to 20 carbon atoms, and more preferably a
methyl.

in order to obtain an N-(O-acylimino)-indane
derivative of formula (IV) :

(IV)



wherein R₁, m and R₂ are as defined above,

20

- a hydrogenolyse-acylation reaction of the
N-(O-acylimino)-indane derivative of formula (IV)
obtained in the previous step,

25

in presence of an organic anhydride of
formula (VI) as defined above and of an heterogeneous
catalyst based on a metal transition selected in the
group comprising Pt, Pd, Ir, Rh and Ni,

in order to obtain an en-amide derivative of formula (III).

5 The molar ratio of the organic anhydride of formula (VI) to the alpha-hydroxyimino-indane derivative of formula (V) used during the acylation reaction is from 1 : 1 to 5 : 1, and is more preferably 1.5 : 1 to 2 : 1.

10 The acylation reaction is performed under a temperature range from 0 to 80°C, preferably 20°C to 40°C, for a period of time in the range of 1 to 8 hours, preferably 2 to 4 hours.

15 The heterogeneous catalyst used during the hydrogenolyse-acylation reaction of the derivative of formula (IV) is selected in the group comprising PtO₂, Pt/C, Pd/C, Pd(OH)₂/C, Ir/C, Rh/C and Raney Ni.

20 Preferably the heterogeneous catalyst is Ir/C.

25 The effective amount of the heterogeneous catalyst used during the hydrogenolyse-acylation is in an amount from 0.1% to 30% for 1 mole of the N-(O-acylimino)-indane derivative of formula (IV).

30 The reaction of hydrogenolyse-acylation is performed with a hydrogen pressure range from 0.5 to 20 bars under a temperature range from -20 to 150°C, preferably 20 to 120°C, for a period of time in the range from 10 min to three days, preferably from 1 to 24 hours.

The molar ratio of the organic anhydride of formula (VI) to the N-(O-acylimino)-indane derivative of formula (IV) used during the hydrogenolyse-acylation reaction is from 1 : 1 to 5 : 1 and preferably 1.5 : 1
5 to 2 : 1.

The acylation reaction of the derivative of formula (V) and the hydrogenolyse-acylation reaction of the derivative of formula (IV) are respectively
10 performed in an aprotic non-basic solvent selected in the group comprising ether like tetrahydrofuran (THF) and diethyl ether, organic acid alkyl ester like ethyl acetate, aromatic hydrocarbon like toluene, and halogenated hydrocarbon like methylene chloride.
15 Preferably the aprotic non-basic solvent is an ether, more preferably THF.

The organic anhydride of formula (VI) used during the acylation reaction and the hydrogenolyse-
20 acylation reaction is selected in the group comprising dialkyl anhydride, diaryl anhydride and alkylarylanhydride, and is preferably an acetic anhydride. The preferred organic anhydride is acetic anhydride.
25

The derivatives of formula (V) (alpha-hydroxyimino-indane) or (IV) (N-(O-acylimino)-indane)) may be used as a syn-form, anti-form or a mixed form of both.

In a preferred embodiment, the two step previously described (the acylation reaction of the derivatives of formula (V) and the hydrogenolyse-


acylation reaction of derivatives of formula (IV)) are carried out in one step (also called "one pot" process).

Thus, the derivative of formula (III) is obtained
5 directly from the derivative of formula (V) without isolating specifically the derivative of formula (IV).

The present invention has also for object the en-amide derivative of formula (III) :

10

(III)



wherein

m is an integer equal to 0, 1, 2 or 3,


15 R₁ is a hydrogen atom, an alkyl group having from 1 to 20 carbon atoms, an aryl group having from 6 to 20 carbon atoms, an alkylaryl group having from 6 to 20 carbon atoms, an alkaloyl group, an aryloyl group, preferably R₁ is an alkyl group having from 1 to 20 carbon atoms, more preferably R₁ is an alkyl group having from 1 to 4 carbon atoms,

20 R₂ is an hydrogen, an alkyl group having from 1 to 20 carbon atoms, an aryl group having from 6 to 20 carbon atoms, an alkylaryl group having from 6 to 20 carbon atoms, preferably R₂ is an alkyl group having from 1 to 20 carbon atoms.

The present invention has also for object the optically active substituted alpha-indanyl amide derivatives of formula (I) :

5

(I)



wherein

10 m is an integer equal to 0, 1, 2 or 3,

 m is an integer equal to 0, 1, 2 or 3,

 R₁ is a hydrogen atom, an alkyl group having from 1 to 20 carbon atoms, an aryl group having from 6 to 20 carbon atoms, an alkylaryl group having from 6 to 20 carbon atoms, an alkaloyl group, an aryloyl group, preferably R₁ is an alkyl group having from 1 to 20 carbon atoms, and more preferably R₁ is an alkyl group having from 1 to 4 carbon atoms,

20 as synthetic intermediates for the preparation of active pharmaceuticals.

 The figure 1 is an illustration of the different steps of the new process of the invention for the synthesis of substituted alpha-aminoindan derivatives. The first step of the process relates to acetylation of the corresponding oxime function of the derivatives of formula (V) in the presence of an organic anhydride of formula (VI) in an appropriate solvent to obtain the derivatives of formula (IV).

The second step of the process relates to a hydrogenolyse-acylation of the intermediates of formula (IV) in presence of a heterogeneous catalyst based on a metal transition and an organic anhydride of formula 5 (VI) in an appropriate solvent to obtain the derivatives of formula (III).

The third step of the process relates to an asymmetric hydrogenation reaction of the derivatives of formula (III) in presence of hydrogen and optically 10 active catalyst of formula (VII) and an appropriate solvent to obtain optically active alpha-indanyl amide derivatives of formula (II).

The fourth step is a hydrolysis reaction of derivatives of formula (II) to obtain alpha-amino-indan 15 derivatives of formula (I).

The invention will be better understood from the experimental details described in the following examples, which will not limit the scope of the invention in any way.

20 Example 1

Acetylation reaction : Preparation of
Indan-1-on-(O-acetyloxime), methoxy-6 of formula (IV)
(in which R₁ = R₂ = CH₃, m = 0).

25 6-methoxy-indan-1-one-oxime of formula (V)
(in which R₁ = CH₃, m = 0) (30 g, 0.169 mol) is partially dissolved in 180 ml of THF at room temperature. To this solution, acetic anhydride of formula (VI) in which R₂ = R'₂ = CH₃ (47.9 ml, 0.508 30 mol) is added in 15 minutes at 20°C. The reaction mixture is stirred between 20-30°C during 2 hours and is then concentrated. A colorless liquid is obtained which can solidify. The residue is dissolved in

methylene chloride (60 ml). The organic layer is washed with water (60 ml) twice. The organic layer is respectively separated from the aqueous layer, is dried over MgSO₄, is filtered off and is concentrated to obtain 56 g of a white solid product (the indan-1-on-(O-acetyloxime), methoxy-6 of formula (IV)). This product is partially dissolved in MTBE (tert-butyl-methyl ether) (60 ml), is warmed at 55 °C. MTBE (195 ml) is added again slowly to dissolve completely the product. The solution is warmed at reflux temperature during 5 mn. The solution is cooled at room temperature (20 °C) and the solid is filtered off. The solid is dried under vacuum.

28.8 g of white solid (the indan-1-on-(O-acetyloxime), methoxy-6 of formula (IV)) is obtained. The yield is 77%.

Example 2

The preparation of the Acetamide, N-(2,3-dihydro-6-methoxy-1H-inden-1-yl) of formula (III) in which R₁ = R₂ = CH₃, m = 0 .

This example illustrates a "one pot" process from oxime derivative of formula (V) (in which R₁ = CH₃, m = 0).

25 g (0.141 mol) of 6-methoxy-indan-1-one-oxime of formula (V) (in which R₁ = CH₃, m = 0) was dissolved in 190 ml of THF.

The mixture is stirred at room temperature until complete dissolution of the product. Then 40 ml of acetic anhydride of formula (VI) in which R₂ = R'₂ = CH₃ are added drop wise. The reaction mixture is stirred at a temperature between 20-30 °C during 2 hours. 2.5 g of the Ir-carbon (5%) catalyst is added to this reaction mixture. The hydrogenation is carried out

at a hydrogen pressure of 7.4 bars at 70-80 °C during 2 hours 15 minutes. After the catalyst Ir/C is filtered off, the filtrate was concentrated to dryness under reduced pressure. The residue is dissolved in 400 ml of toluene and concentrated to dryness under reduced pressure. The residue is dissolved in 75 ml of toluene, the mixture is stirred at a temperature 20°C during 15 mn. The mixture is filtered. The solid is dried under reduced pressure at a temperature of 40-45 °C.

The compound Acetamide, N-(2,3-dihydro-6-methoxy-1H-inden-1-yl)- is obtained with 84 % yield. The chemical purity is 98.4 %.

Example 3

Preparation of N-(6-methoxy-indan-1-yl)-acetamide (R) of formula (II) (in which R₁ = R₂ = CH₃ and m = 0.)

The molar ratio of the en-amide derivative of formula (III) to the catalyst (VII) during the asymmetric hydrogenation is 500/1.

3 g (0.0148 mol) of N-(6-methoxy-3H-inden-1-yl)-acetamide of formula (III) (in which R₁ = CH₃ and m = 0) was dissolved in 30 ml of methanol and 24 mg (2.95 10⁻⁵ mol) of (R)-Ru(OAc)₂(MeOBIPHEP) of formule (VII) are added . The reaction mixture is flushed with nitrogen (5 times) and is warmed to 40°C. The hydrogenation is carried out with a hydrogen pressure of 8 bars at a temperature of 40 °C during 27 hours. The reaction mixture is concentrated until complete removal of the methanol.

50 ml of toluene are added to the residue and concentrated to dryness. The operation is repeated with 10 ml and 5 ml of toluene. The solid is dried under vacuum.

The yield is 89 % and the enantiomeric excess (e.e.) is 84.5 %. Then the product is recrystallized in 15 ml of toluene. The yield is 80 % and the enantiomeric excess (e.e.) is > 98 %.

5

Example 4

Preparation of N-(6-methoxy-indan-1-yl)-acetamide (R) of formula (II) (in which R₁ = CH₃ and m = 0.)

10 The reaction is carried out in the same manner as in example 3, except that the molar ratio of the en-amide derivative of formula (III) to the catalyst (VII) during the asymmetric hydrogenation is 100/1 and the hydrogenation is carried out at 30 °C. The yield is 95 % and the enantiomeric excess (e.e.) is 15 86.6 %. Then the product is recrystallized in toluene. The yield is 77 % and the enantiomeric excess is 98,2 %.

Example 5

Preparation of 6-methoxy-indan-1-ylamine (R) of formula (I) (in which R₁ = CH₃ and m = 0.)

20 1.5 g of N-(6-methoxy-indan-1-yl)-acetamide (R) of formula (II) (in which R₁ = CH₃ and m = 0) is dissolved in methanol (13 ml). To this methanolic solution of the product a solution of hydrochloric acid 25 36 % is added (2.2 ml). The mixture is warmed at 90 °C during 8 hours.

After the mixture is cooled down to 25 °C, a solution of hydrochloric acid (1.1 ml) is added again and the mixture is warmed at 90 °C during 7 hours. 30 After the mixture is cooled down to 25 °C, the same operation is repeated with the solution of hydrochloric acid (0.5 ml) and the mixture is warmed at 90 °C during 6 hours. The mixture is concentrated to remove the

methanol. Water is added (6.5 ml) to the residue and the mixture is concentrated until the complete removal of methanol. The mixture is warmed at 60 °C and water (7 ml) is added to complete dissolution of the product.






5 Toluene (8 ml) is added to the solution. After removal of the organic layers, the aqueous layer is basified with soda 30 % until a pH range 12 to 13 in presence of xylenes (5 ml) at a temperature 22 °C. The aqueous layer is separated and re-extracted with xylenes (8 ml)

10 3 times. All organic layers are mixed and concentrated to dryness. The product is obtained with 65 % yield.

Asymmetric hydrogenation reactions were performed using different ligand and conditions according to the protocol of Example 3. The results are

15 summarized in the following table for each example.


Ex.	chiral ligand	S/C	Pressure H ₂ bar	Temp. °C	Time	% e.e.
6	(1 <i>S</i> , 1 <i>S'</i> , 2 <i>R</i> , <i>R'</i>) Tangphos	110	6	25	45 mn	93.8% (R)
7	(1 <i>S</i> , 1 <i>S'</i> , 2 <i>R</i> , <i>R'</i>) Tangphos	1000	12	25	18 h	89.8% (R)

Ex.	chiral ligand	S/C	Pressure H ₂ bar	Temp. °C	Time	% e.e.
8	(S) Binaphane 	110	6	25	45 mn	95.8% (R)
9	(R,R) 	110	6	25	10-12 h	72.3% (R)
10 preformed catalyst	(S,S) 	110	6	25	1-1h30	84.2% (S)
11 preformed catalyst	(R,R)MeBPE 	110	6	25	15 mn	97.9% (R)
12	(R,R)MeBPE 	110	6	25	30 mn	98.2% (R)

Ex.	chiral ligand	S/C	Pressure H ₂ bar	Temp. °C	time	% e.e.
13 preformed catalyst	(R,R)MeBPE 	10000	6	50	24 h	95.2% (R)
14	(R,R)EtBPE 	110	6	25	45 mn	97% (R)

CLAIMS.

1. A process for the preparation of optically active substituted alpha-indanyl amide derivatives of formula (I) :



10 wherein


m is an integer equal to 0, 1, 2 or 3,

R₁ is a hydrogen atom, an alkyl group having from 1 to 20 carbon atoms, an aryl group having from 6 to 20 carbon atoms, an alkylaryl group having from 6 to 20 carbon atoms, an alkaloyl group, an aryloyl group,

which comprise :

- an asymmetric hydrogenation reaction of an en-amide derivative of formula (III)

(III)



20

wherein m and R₁ are as defined above,


R2 is a hydrogen atom, an alkyl group having from 1 to 20 carbon atoms, an aryl group having from 6 to 20 carbon atoms, an alkylaryl group having from 6 to 20 carbon atoms,

5

in presence of hydrogen and an optically active catalyst,

10 in order to obtain an amide derivative of formula (II) :

(II)



(R) ou (S)

15 - a hydrolysis reaction of the amide derivative of formula (II) obtained in the previous step,

20 in order to obtain optically active substituted alpha-indanyl amide derivatives of formula (I).

25 2. Process according to claim 1, wherein the optically active catalyst used in the asymmetric hydrogenation of the en-amide derivative of formula (III) is represented by a chiral phosphine transition metal complexe of formula (VIIA) :

$$M(X)_j(Z)_i(L^*)(Y)_n \quad (VIIA)$$

wherein

M is a transition metal selected in the group comprising ruthenium (Ru), rhodium (Rh) and
5 iridium (Ir)

X is a halogen atom selected in the group comprising chlore (Cl), bromine (Br), fluor (F) and iodine (I),

10 Z is an aryl group having from 6 to 20 carbon atoms or an unsaturated organic group, cyclic or not, selected in the group comprising olefine, diene and cyano,

15 L* is a chiral ligand selected in the group comprising the chiral diphosphine derivatives, the chiral atropoisomeric diphosphine derivatives, the chiral monodentate phosphoramide derivatives, the chiral biphospholane derivatives, the chiral ferrotane derivatives and the chiral ferrocenyl phosphine derivatives,

20 Y is an anion such as ClO_4^- , BF_4^- , PF_6^- , SbF_6^- ,

j is an integer equal to 0 or 1,

i is an integer equal to 0, 1, 2 or 4,

n is an integer equal to 1 or 2.

25 3. Process according to claim 1, wherein the optically active catalyst used in the asymmetric hydrogenation of the en-amide derivative of formula (III) is represented by a chiral phosphine transition metal complexe of formula (VIIB) :

30 $[\text{M}(\text{X})(\text{L}^*)]_2(\text{X})_3 \text{ S}$ (VIIB)

wherein

M is a transition metal selected in the group comprising ruthenium (Ru), rhodium (Rh) and iridium (Ir),

X is a halogen atom selected in the group comprising chlore (Cl), brome (Br), fluor (F) and iodine (I),

L* is a chiral ligand selected in the group comprising the chiral diphosphine derivativee, the chiral atropoisomeric diphosphine derivatives, the chiral monodentate phosphoramidine derivatives, the chiral biphospholane derivatives, the chiral ferrotane derivatives and the chiral ferrocenyl phosphine derivatives,

S is a primary amine,

j is an integer equal to 0 or 1,

i is an integer equal to 0, 1, 2 or 4,

n is an integer equal to 1 or 2.

4. The process according to claim 2, wherein the olefine is selected in the group comprising pi-allyl and 1,3,5,7-cyclooctatetraene and the diene is selected in the group comprising 1,3-butadiene, 2,5-norbornadiene, 1,5-cyclooctadiene (COD) and cyclopentadiene.

25

5. The process according to claim 2, wherein the aryl group is a benzene optionally substituted with an alkyl.

30

6. The process according to any one of claims 2 or 3, wherein the chiral diphosphine is selected in the group comprising BICP, DuPHOS,

MiniPHOS, BDPMI, TangPHOS, P-PHOS, Tol-P-PHOS, Xyl-P-PHOS and BPE.

7. The process according to any of claims 2
5 or 3, wherein the chiral atropoisomeric diphosphine is selected in the group comprising BINAP, TolBINAP, MeOBIPHEP, BINAPO, SYNPHOS and BINAPO optionally ortho-substituted with an alkyl or an aryl.

10 8. The process according to any of claims 2 or 3, wherein the chiral monodentate phosphoramidine is selected in the group comprising Monophos and Ethylmonophos.

15 9. The process according to any of claims 2 or 3, wherein the chiral bisphospholane is selected in the group comprising Tangphos, Duphos, Me-Duphos Me-BPE, Et-BPE, Binaphane and Malphos.

20 10. The process according to any of claims 2 or 3, wherein the chiral ferrocenyl phosphine is JOSIPHOS.

25 11. The process according to any one of claims 1 to 10, wherein the optically active catalyst is $\text{Ru}(\text{COD})(\text{MeOBIPHEP})\text{BF}_4^-$, $\text{Ru}(\text{COD})(\text{BINAP})\text{BF}_4^-$ or $\text{Rh}(\text{COD})(\text{Me-BPE})\text{BF}_4^-$.

30 12. The process according to any one of claims 1 to 11, wherein the solvent used during the asymmetric hydrogenation is selected in the group comprising ether, aromatic hydrocarbon halogenated hydrocarbon and alcohol, preferably an alcohol.

13. The process according to claim 12,
wherein the ether is selected in the group comprising
tetrahydrofuran (THF), tetrahydropyran and diethyl
5 ether, the aromatic hydrocarbon is selected in the
group comprising benzene and toluene, the halogenated
hydrocarbon is dichloromethane, the alcohol is selected
in the group comprising methanol, ethanol and
isopropanol, and is preferably the methanol.

10

14. The process according to any one of
claims 1 to 13, wherein the molar ratio of the en-amide
derivative of formula (III) to the catalyst (VII) used
during the asymmetric hydrogenation is from 100/1 to
15 10000/1, preferably from 100/1 to 1000/1 and is more
preferably from 200/1 to 1000/1.


15. The process according to any one of
claims 1 to 14, wherein the hydrogen pressure used
20 during the asymmetric hydrogenation is from 0,5 to 20
bars, preferably from 0,5 to 10, and more preferably 1
to 8.

16. The process according to any one of
25 claims 1 to 15, wherein the temperature range used
during the asymmetric hydrogenation is from - 20 to
100°C, preferably from 20 to 100°C, and more preferably
20°C to 60°C.

30 17. The process according to any one of
claims 1 to 16, wherein the en-amide derivative of
formula (III) is prepared by the two following step :

- an acylation reaction of an alpha-hydroxyimino-indane derivative of formula (V) :


(V)



5

wherein R₁ and m are as defined above
in presence of an organic anhydride of
formula (VI) :


10



wherein R₂ and R'₂ identical or different
are a hydrogen atom, an alkyl group having from 1 to 20
15 carbon atoms, an aryl group having from 6 to 20 carbon
atoms, an alkylaryl group having from 6 to 20 carbon
atoms,

in order to obtain an N-(O-acylimino)-indane
20 derivative of formula (IV) :

(IV)



wherein R₁, m and R₂ are as defined above,

5

- a hydrogenolyse-acylation reaction of the N-(O-acylimino)-indane derivative of formula (IV) obtained in the previous step,

10 in presence of an organic anhydride of formula (VI) as defined above and of an heterogeneous catalyst based on a metal transition selected in the group comprising Pt, Pd, Ir, Rh and Ni,

in order to obtain an en-amide derivative of formula (III).

15

18. The process according to claim 17, wherein the molar ratio of the organic anhydride of formula (VI) to the alpha-hydroxyimino-indane derivative of formula (V) used during the acylation reaction is from 1 : 1 to 5 : 1 and preferably 1.5 : 1 to 2 : 1.

20
25 19. The process according to claim 17 or 18, wherein the heterogeneous catalyst used during the hydrogenolyse-acylation reaction of the derivative of formula (IV) is selected in the group comprising PtO₂,

Pt/C, Pd/C, Pd(OH)₂/C, Ir/C, Rh/C and Raney Ni, and is preferably Ir/C.

20. The process according to any one of
5 claims 17 to 19, wherein the effective amount of the heterogeneous catalyst used during the hydrogenolyse-acylation is in an amount from 0.1% to 30% for 1 mole of the N-(O-acylimino)-indane derivative of formula (IV).

10

21. The process according to any one of claims 17 to 20, wherein the molar ratio of the organic anhydride of formula (VI) to the N-(O-acylimino)-indane derivative of formula (IV) used during the 15 hydrogenolyse-acylation reaction is from 1 : 1 to 5 : 1 and preferably 1.5 : 1 to 2 : 1.

22. The process according to any one of claims 17 to 21, wherein the acylation reaction of the 20 derivative of formula (V) and the hydrogenolyse-acylation reaction of the derivative of formula (IV) are respectively performed in an aprotic non-basic solvent selected in the group comprising ether, organic acid alkyl ester, aromatic hydrocarbon and 25 halogenated hydrocarbon.

23. The process according to any one of claims 17 to 22, wherein the organic anhydride of formula (VI) used during the acylation reaction and the 30 hydrogenolyse-acylation reaction is selected in the group comprising dialkyl anhydride, diaryl anhydride and alkylarylanhydride, and is preferably an acetic anhydride.

24. The process according to any one of
claims 17 to 23, wherein the derivative of formula
(III) is obtained directly from the derivative of
5 formula (V) without isolating specifically the
derivative of formula (IV).

1/1




Figure 1

INTERNATIONAL SEARCH REPORT

Int'l	Application No
PCT/IB2005/000534	

A. CLASSIFICATION OF SUBJECT MATTER		
IPC 7	C07C213/02	C07C217/54

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT		
---	--	--

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98/27055 A (TECHNION RES & DEV FOUNDATION ; WEINSTOCK ROSIN MARTA (IL); YISSUM RES) 25 June 1998 (1998-06-25) cited in the application see scheme I	1-24

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
---	--

12 July 2005	27/07/2005
--------------	------------

Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer
--	--------------------

Goetz, G

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte al Application No

PCT/IB2005/000534

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 9827055	A	25-06-1998	AT 292619 T	15-04-2005
			AU 5726898 A	15-07-1998
			CA 2275425 A1	25-06-1998
			DE 69732984 D1	12-05-2005
			EP 1535902 A1	01-06-2005
			EP 0966435 A1	29-12-1999
			HU 0101130 A2	28-08-2001
			IL 130528 A	15-12-2004
			JP 2001506269 T	15-05-2001
			WO 9827055 A1	25-06-1998
			US 6462222 B1	08-10-2002
			US 2002188020 A1	12-12-2002